Clinical Trial Update: Multi-Center, Open-Label, 24-Week Study of OX219 Safety and Efficacy for Maintenance Treatment of Opioid Dependence [Phase 4]

View source ↗

Summary

OX219 was studied in a multi-center, open-label Phase 4 trial to assess safety and efficacy as maintenance treatment in opioid-dependent patients on agonist the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Dependence

Drugs mentioned

• OX219

Snippet

Sponsor: Orexo AB | Conditions: Opioid Dependence, on Agonist Therapy | Phase 4 | Status: COMPLETED | Results posted: 2015-10-28